The DAPA-CKD, CREDENCE, and EMPA-KIDNEY studies provide strong evidence for the efficacy of SGLT-2 inhibitors (such as Dapagliflozin, Canagliflozin, and Empagliflozin) in CKD. Here, SLC5A2 is linked to chronic kidney disease.